Table 1. Characteristics of vaccinated patients.

n (%) or median [IQR]	Non-responders N = 23	Responders N = 6		p*
Age (y)	61.2 [45.8; 70.1]	47.7 [41.2; 61.7]		0.254
Male	14 (61)	4 (67)		>0.999
BMI	24.9 [23.8; 29.4]		23.8 [20.2; 24.5]	0.138
Comorbidities Cardiopathy Diabetes	15 (65) 3(13)		6 (100) 0 (0)	0.138 >0.999
Time since transplantation (y)	7.0 [1.6; 15.9]		10.4 [3.5; 24.6]	0.414
Donor type Deceased Living	20 (87) 3 (13)	5 (83) 1 (17)		>0.999
Induction therapy Anti-thymocyte globulins Basiliximab No induction NA	13 (57) 8 (35) 1 (4) 1 (4)	4 (67) 1 (17) 1 (17) 0 (0)		0.453
Maintenance immunosuppression CNI (yes) MMF/MPA (mg/day) Steroids (mg/day) imTOR (yes) Belatacept (yes)	22 (96) 1000 [500; 1000] 5.0 [0.0; 5.0] 1 (4) 1 (4)	6 (100) 250 [0; 625] 2.5 [0.0; 5.0] 2 (33) 0 (0)		>0.999 0.014 0.358 0.100 >0.999
Biological data Lymphocytes (G/L) Monocytes (G/L) CRP (mg/L) Albumin (g/L) Creatinine (μmol/L)	1.16 [0.99; 1.38] 0.55 [0.41; 0.79] 4.0 [4.0; 5.8] 43 [42; 46] 134 [97; 183]	1.99 [1.45; 2.66] 0.51 [0.44; 0.70] 4.5 [4; 10.6] 44 [43; 45] 131 [97; 237]		0.069 0.723 0.570 0.874 0.859

*qualitative variables were compared using a Fisher or Chi-square test, quantitative variables were compared using a Mann-Whitney test. IQR: interquartile range; y, years; BMI, body mass index; NA, not available; CNI: calcineurin inhibitor; MMF/MPA: mycophenolate mofetil/mycophenolic acid; imTOR, inhibitor of the mechanistic target of rapamycin; CRP, C-reactive protein.